BMS gets a key strategist with 'Team Shibs' Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Th Fri 13 June, 2025

Supply chain strategy just got more complicated — is your manufacturing model still viable? Trade tensions, policy shifts, and geopolitical uncertainty have biopharma executives rethinking manufacturing and distribution. How are the experts doing it now? Find out — get your spot today.

presented by McKesson leads the charge in rev­o­lu­tion­iz­ing pre­ci­sion on­col­o­gy in com­mu­ni­ty prac­tices

spotlight Who are the women reshaping biopharma R&D? Nominate them for Endpoints' annual report

news AstraZeneca inks AI drug R&D deal with Chinese pharma for $110M upfront  Moderna wins expanded label for RSV shot, allowing use in at-risk, younger adults Peer Review Bristol Myers gets a key strategist with 'Team Shibs'; Idorsia to change CEOs after it 'hit a reset button' Novo Nordisk plans Phase 3 trials of oral, injectable amycretin for early 2026

Jun 18 12:00pm ET Illuminating the CKD patient journey: Clinicogenomic data reshapes research & drug discovery sponsored by Natera Jun 24 10:30am ET Expanding access, accelerating trials: The power of community-based oncology research sponsored by START Research Jun 26 11:00am ET May the (Power of the) Pool be with you: Accelerating time from DNA to GMP – STI based CLD Platform sponsored by Rentschler Biopharma Jul 10 11:00am ET Beyond the data deluge: Immune profiling in early immuno-oncology trails sponsored by Precision for Medicine

endpoints pharma CureVac CEO on BioNTech deal: Come together 'rather than fighting each other in court' •  BioNTech to acquire CureVac in all-stock deal valued at $1.25B In surprise, FDA approves UroGen's chemo-turned-gel drug after negative adcomm vote Exclusive: Kennedy picks for vaccine advisory board were paid experts against Merck in civil cases Kennedy's vaccine doubts hinge on 'inert' placebos, but experts say he misunderstands the science Minnesota generic drug pricing law is likely unconstitutional, appeals court rules

in case you missed it 1. Insmed aims to raise $750M in one of the largest stock offerings this year 2. Kura, Kyowa say Phase 1 update supports menin inhibitor combos  3. Schrödinger says early MALT1 data could lay 'great foundation' for combos 4. News Briefing